8-K: Monogram Technologies Provides Regulatory Update on mBs TKA System and Clinical Trial Preparation in India

Monogram Technologies announces completion of supplemental testing and submission of formal response to the FDA for its mBs TKA System, while also progressing with clinical trial preparations in India.

Summary

• Monogram Technologies Inc. has provided an update on its regulatory progress for the mBs TKA System and its clinical trial preparation in India.
• The company has completed all supplemental testing and submitted its formal response to the FDA regarding the Additional Information Request (AIR) received on September 30, 2024.
• Monogram does not anticipate further requests for information from the FDA and expects a clearance decision for the mBs Total Knee Arthroplasty (TKA) System.
• In August 2024, Monogram announced a strategic collaboration with Shalby Limited to conduct a multicenter clinical trial in India.
• In January 2025, the company shipped a robot to support clinical trial training, and an Investigator Meeting was held in Ahmedabad, India, from January 31 to February 1, 2025.
• The meeting was organized by Reliance Life Sciences and attended by principal investigators, surgeons, and staff to review study protocols and regulatory requirements.
• Monogram has submitted its system for regulatory clearance to run the clinical trial and will provide updates as they occur.
• The company has refined its cutting system, achieving an approximately 300% increase in feed rate.
• Monogram remains focused on developing a multi-application robotic system that is time-competitive with manual surgery without compromising accuracy or safety.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the progress in regulatory submissions and clinical trial preparations. The advancements in the cutting system and management's confidence in the technology contribute to the positive outlook. However, the cautionary note regarding forward-looking statements and inherent risks tempers the overall sentiment.

Positives

• The company has completed all supplemental testing and submitted its formal response to the FDA.
• Monogram anticipates a clearance decision from the FDA for its mBs TKA System.
• The Investigator Meeting in India was a successful milestone in preparing for the clinical trial.
• The cutting system has been refined, resulting in an approximately 300% increase in feed rate.
• Monogram is focused on developing a robotic system that is time-competitive with manual surgery.

Risks

• The company's lack of profitability and need for additional capital to grow its business.
• Dependence on partners to further the development of its product candidates.
• Uncertainties inherent in the development, attainment of regulatory authorizations and approvals, and launch of any new product.
• The outcome of pending or future litigation.
• Regulatory timelines can be variable.

Future Outlook

The company anticipates a clearance decision from the FDA for its mBs Total Knee Arthroplasty (TKA) System and remains confident in its submission and strategic partnerships to support the clinical trial process in India. Monogram continues to refine its technology to improve system performance and usability as it progresses toward commercialization.

Management Comments

• Dr. Douglas Unis, Monogram's Chief Medical Officer, commented, 'The latest advancements in Monogram's robotic system are a game changer. The new cutting system enables cutting speeds that are becoming competitive with manual surgery while maintaining the accuracy and functionality expected from robotic-assisted procedures.'
• Ben Sexson, CEO, stated, 'We have completed all proposed testing with what we view to be favorable results and we remain focused on developing a robotic platform that surgeons will want to use.'

Industry Context

This announcement highlights Monogram Technologies' progress in the competitive orthopedic robotics market. The company's focus on AI-driven robotics and personalized implants aligns with the industry's trend toward precision medicine and minimally invasive surgery. The collaboration with Shalby Limited and Reliance Life Sciences demonstrates a strategic approach to expanding into the Indian market.

Comparison to Industry Standards

• The 300% increase in feed rate for the cutting system is a significant improvement, potentially making Monogram's system more competitive with manual surgery times, a key factor for surgeon adoption.
• Companies like Stryker, Zimmer Biomet, and Smith+Nephew are major players in the orthopedic robotics market, and Monogram's success will depend on its ability to differentiate its technology and demonstrate superior clinical outcomes.
• The collaboration with Shalby Limited, a leading orthopedic hospital group in India, provides Monogram with a valuable platform for clinical trials and potential market entry.

Stakeholder Impact

• Shareholders: Positive news regarding regulatory progress and clinical trial preparations may increase investor confidence.
• Surgeons: Advancements in the robotic system, particularly the increased cutting speed, could make the technology more appealing.
• Patients: Successful development and commercialization of the mBs TKA System could lead to improved outcomes and personalized knee replacements.

Next Steps

• Await FDA clearance decision for the mBs Total Knee Arthroplasty (TKA) System.
• Continue clinical trial preparations in India with Reliance Life Sciences and Shalby Limited.
• Continue refining and enhancing next-gen technology.

Key Dates